Rethinking Obesity Strategies: The Rise of GLP-1 Drugs and Lifestyle Programs for Weight Loss
Thursday, June 15
11:30am PT / 2:30pm ET
Bank of America analyst, Geoff Meacham, believes that Mounjaro, an increasingly popular GLP-1 drug for weight loss, could be the first $100B pharmaceutical. He estimates Mounjaro can achieve sales of 4–5x the current best selling drug, Humira.
GLP-1s have been around for over twenty years, but have skyrocketed in popularity this year as indications expand to patients with obesity. With an annual price tag of $12,000+ per patient per year, possibly for the rest of the patient’s life, the cost to employers and health plans will be staggering.
Whether your organization has felt the tidal wave of GLP-1 claims yet or not—it’s coming. And while GLP-1s have been shown to help patients rapidly lose weight - concerns remain about utilization management, cost-effectiveness, the emergence of “digital pill mills”, and aggressive pharmaceutical marketing practices.
Employers and health plans have a new set of options to navigate this spike, but the time to reconsider obesity strategies is now. Join this session to learn more, including:
- What health plan leaders are seeing when it comes to GLP-1s and how they’re responding, as reported in a new national survey
- Mitigation strategies including changes to plan design, incentives, combo therapy, step therapy or prior authorization, and targeted marketing
- Lifestyle programs that are successfully addressing obesity - without the use of a doctor’s prescription pad
- Why informed member choice must be at the center of your strategy
Register to save your spot or get a copy of the recording after the live webinar.
Register for the webinar
About the Speakers
Sara Izadi, PharmD
SVP Pharmacy, Capital Rx
Sara is responsible for overseeing and managing all aspects of Clinical functions at Capital Rx. She leverages more than a decade of experience across pharmacy benefits, physician organizations, hospitals, retail pharmacies, and clinical research to develop and guide clinical operations. Before Capital Rx, Sara served as Senior Pharmacist and Program Lead for an OptumCare independent physician organization where she led the development of the Pharmacy Department, transformed the utilization management process, and implemented multiple clinical programs overseeing drug utilization for more than a million covered members.
Adam Wolfberg, MD
Chief Medical Officer, Virta Health
Dr. Wolfberg brings over two decades of experience as both a practicing physician and a medical leader at fast-growing digital health companies to his role at Virta. Most recently, Dr. Wolfberg served as Chief Medical Officer (CMO) at Current Health (acquired by Best Buy) and at Ovia Health (acquired by LabCorp). He’s also held clinical leadership roles at athenahealth and several other health technology companies, while seeing patients at Cambridge Health Alliance.
Copyright © 2023 All Rights Reserved